Terns Pharmaceuticals Inc (TERN) Stock
TERN is no longer traded. Terns Pharmaceuticals was delisted from the Nasdaq in April 2026.
Prices on this page are historical; the last trade was April 28, 2026 at $52.94.
Terns Pharmaceuticals stock price history
TERN final trading statistics
- Final close
- $52.94
- Final trading day
- Apr 28, 2026
- Market cap at delisting
- $6.12B
- Shares outstanding
- 115.52M
- Final 52-week range
- $2.65 – $53.19
- Avg. volume (final 3 mo.)
- 5,674,110
- All-time high (split-adj.)
- $53.17 · Mar 2026
- All-time low (split-adj.)
- $1.50 · May 2022
- Return since IPO
- +187.9%
- Beta
- -0.38
- Book value / share
- $8.96
- Price / book
- 5.91
Terns Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0.00 | -$96.2M | -$1.03 |
| FY2024 | $0.00 | -$88.9M | -$1.13 |
| FY2023 | $0.00 | -$90.2M | -$1.27 |
| FY2022 | $0.00 | -$60.3M | -$1.83 |
| FY2021 | $1.00M | -$50.2M | -$2.34 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Terns Pharmaceuticals stock FAQ
What happened to Terns Pharmaceuticals stock?
Terns Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $52.94 on April 28, 2026.
Is TERN stock still trading?
No. TERN was delisted from the Nasdaq in April 2026 and no longer trades on a U.S. exchange.
What was the last price of TERN stock?
TERN closed at $52.94 on its final trading day, April 28, 2026, for a market value of about $6.12B.
What were Terns Pharmaceuticals's revenue and earnings in its last full fiscal year?
Terns Pharmaceuticals reported revenue of $0.00 and net income of -$96.2M in fiscal 2025, its last full year as a public company.
When did Terns Pharmaceuticals go public?
Terns Pharmaceuticals Inc stock began trading on February 5, 2021.